TY - T1的衰老和死亡的表观遗传血液生物标志物在慢性阻塞性肺病JF -欧洲呼吸杂志乔——欧元和J - 10.1183/13993003.01890 -2021 SP - 2101890 AU -安娜我埃尔南德斯Cordero盟陈曦杨盟——斯蒂芬·米尔恩Zsuzsanna打浆机AU -宣李盟盟Raymond Ng -维吉尼亚陈盟盟-斯科特·J Tebbutt盟Janice M梁AU - D罪不Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/09/09/13993003.01890 - 2021. -抽象N2 -慢性阻塞性肺疾病(COPD)是一种与年龄相关的条件,与细胞衰老[1]。在慢性阻塞性肺病,细胞衰老的贡献者包括氧化应激环境因素如吸烟和持久的肺部炎症[2]。这些因素也可以增加复制衰老,特点是进步的端粒磨损,最终导致细胞周期阻滞和死亡。COPD患者有较短的端粒[3]和更快的端粒磨损率[4]相比,控制;然而,细胞或复制衰老在慢性阻塞性肺病的临床影响尚不确定。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。这些生产过程完成后,作者已经批准结果证明,本文将最新一期的ERJ在线。请打开或下载PDF查看这篇文章。利益冲突:人工智能埃尔南德斯Cordero没有披露。利益冲突:李从先杨没有披露。利益冲突:美国米尔恩没有披露。利益冲突:李x没有披露。Conflict of interest: Z. Hollander reports funding from Genome Canada, Genome British Columbia, Genome Quebec, the Canadian Institutes of Health Research, PROOF Centre of Excellence, St. Paul's Hospital Foundation and Providence Health Care for the Rapid Transition Program (RTP) cohort included in the manuscript.Conflict of interest: V. Chen reports funding from Genome Canada, Genome British Columbia, Genome Quebec, the Canadian Institutes of Health Research, PROOF Centre of Excellence, St. Paul's Hospital Foundation and Providence Health Care for the Rapid Transition Program (RTP) cohort included in the manuscript.Conflict of interest: R. Ng reports funding from Genome Canada, Genome British Columbia, Genome Quebec, the Canadian Institutes of Health Research, PROOF Centre of Excellence, St. Paul's Hospital Foundation and Providence Health Care for the Rapid Transition Program (RTP) cohort included in the manuscript.Conflict of interest: S.J. Tebbutt has nothing to disclose.Conflict of interest: J.M. Leung reports research research grant funding to their institution from Canadian Institutes of Health Research, Michael Smith Foundation for Health Research, BC Lung Association and Genome BC, outside the scope of the current manuscript.Conflict of interest: D.D. Sin declares grants from AstraZeneca for an investigator-initiated randomised controlled trial in COPD; consulting fees from Novaira for sitting on an advisory board for COPD; and honoraria for speaking engagements from AstraZeneca, Boehringer Ingelheim and Grifols, all in the 36 months prior to manuscript submission. ER -